Comparing Oral S-1 and IV 5-Fluorouracil in Cancer Treatment
Author Information
Author(s): Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S
Primary Institution: National Cancer Center Hospital
Hypothesis
The study aims to investigate the differences in pharmacokinetics and pharmacodynamics between oral S-1 and protracted venous infusion (PVI) of 5-fluorouracil.
Conclusion
Oral S-1 produces higher plasma concentrations of 5-FU compared to PVI of 5-FU, with lower levels of its toxic metabolite FBAL.
Supporting Evidence
- The Cmax and AUC of 5-FU were significantly higher during S-1 treatment compared to PVI.
- Plasma FBAL concentrations were significantly lower during S-1 treatment than during PVI of 5-FU.
- Patients experienced fewer side effects with S-1 compared to PVI of 5-FU.
Takeaway
This study shows that taking S-1 by mouth can give patients more of the cancer-fighting medicine 5-FU without increasing harmful side effects.
Methodology
The study involved 10 patients receiving both PVI of 5-FU and oral S-1, with blood samples collected to measure drug concentrations.
Potential Biases
Potential bias due to the small sample size and specific patient demographics.
Limitations
The study had a small sample size and was limited to patients with metastatic gastrointestinal cancer.
Participant Demographics
All participants were between 20 and 75 years old, with a median age of 66, and all had metastatic gastric carcinoma.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website